GlassScriptPhysician profile
Michael Christopher Sparr
NPI 1871501189
$1,452.86
in general payments reported to CMS, 2019-2025
23 companies · $74.71 in 2025
The $74.71 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $433 · 2021: $146 · 2022: $108 · 2023: $117 · 2024: $221 · 2025: $74.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $395.93 | 2019-2024 | Senza |
| Boston Scientific Corporation | $152.36 | 2019-2025 | Intracept |
| Pfizer INC. | $143.08 | 2023-2024 | |
| Abbott Laboratories | $106.99 | 2021-2025 | Eterna, Proclaim |
| Arbor Pharmaceuticals, INC. | $105.43 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.80 | 2019-2020 | |
| Bioventus LLC | $64.98 | 2019-2020 | |
| Merz North America, INC. | $49.68 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $47.28 | 2019 | |
| Sanofi-Aventis U.S. LLC | $39.54 | 2019-2020 | |
| Abbvie INC. | $37.91 | 2023 | Botox |
| Biodelivery Sciences International, INC. | $30.68 | 2019-2020 | |
| Assertio Therapeutics, INC. | $30.56 | 2019 | |
| Almatica Pharma LLC | $25.30 | 2021 | |
| Si-Bone, INC. | $22.51 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $16.48 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.48 | 2022 | |
| Ibsa Pharma INC. | $14.33 | 2022 | |
| Collegium Pharmaceutical, INC. | $14.10 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.68 | 2019 | |
| Mdd US Operations, LLC | $12.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.96 | 2019 | |
| Otto Bock Healthcare LP | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sparr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.